Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint Pharmaceuticals, Inc. - Common Stock (NQ:EYPT)

10.71 -1.68 (-13.52%)
Streaming Delayed Price Updated: 10:53 AM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss
EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data. 
Via Chartmill
Topics Earnings
Earnings Scheduled For November 5, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding. 
Via Benzinga
EyePoint (EYPT) Q2 Revenue Drops 44%
Via The Motley Fool
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Analyst Expectations For EyePoint Pharmaceuticals's Future
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
A Peek at EyePoint Pharmaceuticals's Future Earnings
 
Via Benzinga
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews
 
Via Benzinga
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market
EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid... 
Via Chartmill
Topics Earnings
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals
 
Via Benzinga
Breakout Momentum Plays You May Not Know About
Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth. 
Via MarketBeat
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Analyst Ratings For EyePoint Pharmaceuticals
 
Via Benzinga
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 5, 2025
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Topics Government
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
EYPT stock results show that EyePoint Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.